中药治疗2019冠状病毒病的系统评价与荟萃分析
该系统评价纳入11项RCT或准RCT共1259例COVID-19患者,评估中药联合西药对比单用西药的疗效与安全性。荟萃分析显示联合组在转重率、住院时间、退热时间、咳嗽缓解率、乏力缓解率及气促缓解率方面优于单用西药,安全性无显著差异,但纳入研究方法学质量普遍不明确。
要点
- 中药联合西药可降低COVID-19患者转重及危重型风险(RR=0.47)。
- 联合治疗缩短住院时间(MD=-7.95天)和退热时间(MD=-1.20天)。
- 联合治疗提高咳嗽、乏力、气促缓解率,安全性无显著差异。
核心结论
- 中药联合西药可能为COVID-19患者带来潜在获益。
- 纳入试验质量不够好,仍需高质量研究及核心结局集。
研究设计与样本
- 系统评价与荟萃分析,检索6个数据库至2020年6月。
- 纳入RCT和准RCT,共11项研究1259例患者。
- 采用Cochrane偏倚风险工具评估质量,Review Manager 5.3进行荟萃分析。
主要发现
- 转重及危重型患者数:RR=0.47,95%CI=[0.32,0.69],P<0.0001。
- 住院时间:MD=-7.95,95%CI=[-14.66,-1.24],P=0.02。
- 退热时间:MD=-1.20,95%CI=[-2.03,-0.38],P=0.004。
- 咳嗽缓解率:RR=1.37,95%CI=[1.15,1.64],P=0.0004;乏力缓解率:RR=1.37,95%CI=[1.02,1.83],P=0.04;气促缓解率:RR=2.20,95%CI=[1.11,4.39],P=0.02。
- 安全性方面两组无显著差异。
关键数值与推荐
- 中药包括汤剂和中成药。
- 方法学质量总体评价为不明确。
临床怎么用
- 在COVID-19治疗中可考虑中药联合西药以降低转重风险、缩短住院和退热时间。
- 使用时应关注纳入研究质量不高的局限性,结合临床实际谨慎决策。
局限性
- 纳入试验方法学质量普遍不明确。
- 仍需高质量研究及核心结局集进一步验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Integration of Chinese medical drugs (CMD) and western medicine (WM) has been widely used in the treatment of Coronavirus Disease 2019 (COVID-19). This systematic review aimed to evaluate the efficacy and safety of CMD for COVID-19. METHOD: A literature search was performed in six databases from injection to June 2020. Both randomized controlled trials (RCTs) and quasi-RCTs were considered as eligible. The quality of included RCTs were assessed by Cochrane Risk of Bias Tool, and Review Manager 5.3 software was used to do meta-analysis. RESULT: Eleven studies with 1259 patients were included in this study. CMD included herbal decoction and Chinese patent medicine. The methodological quality was evaluated as generally unclear. The results of meta-analysis showed that the integration of CMD and WM had better efficacy than WM in number of patients turned to severe and critical type (RR = 0.47, 95% CI=[0.32, 0.69], P < 0.0001), length of hospital stay (MD= -7.95, 95% CI=[-14.66, -1.24], P = 0.02), defervescence time (MD= -1.20, 95% CI=[-2.03, -0.38], P = 0.004), cough resolution rate (RR = 1.37, 95% CI=[1.15, 1.64], P = 0.0004), fatigue resolution rate (RR = 1.37, 95% CI=[1.02, 1.83], P = 0.04), and tachypnea resolution rate (RR = 2.20, 95% CI=[1.11, 4.39], P = 0.02). As for safety, there was no significant difference between two groups. CONCLUSION: CMD may bring potential benefit to patients suffered from COVID-19. However, the quality of included trials is not good enough. High quality study with core outcome set are still required.
引用
- Pang W, Liu Z, Li N, et al. Chinese medical drugs for coronavirus disease 2019: A systematic review and meta-analysis. Integr Med Res. 2020. PMID: 32834992. doi:10.1016/j.imr.2020.100477
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。